Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Secondary mutations of BRCA1/2 and drug resistance.

Dhillon KK, Swisher EM, Taniguchi T.

Cancer Sci. 2011 Apr;102(4):663-9. doi: 10.1111/j.1349-7006.2010.01840.x. Epub 2011 Jan 30. Review.

2.

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.

Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T.

Nature. 2008 Feb 28;451(7182):1116-20. doi: 10.1038/nature06633. Epub 2008 Feb 10.

3.

Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.

Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM.

J Clin Oncol. 2017 Apr 10;35(11):1240-1249. doi: 10.1200/JCO.2016.71.3677. Epub 2017 Feb 21.

PMID:
28221868
4.

[Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].

Kluzek K, Białkowska A, Koczorowska A, Zdzienicka MZ.

Postepy Hig Med Dosw (Online). 2012 Jun 15;66:372-84. Review. Polish.

5.
6.

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].

Schreiber V, Illuzzi G, Héberlé E, Dantzer F.

Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15. Review. French.

PMID:
26384693
7.

Drug resistance caused by reversion mutation.

Ashworth A.

Cancer Res. 2008 Dec 15;68(24):10021-3. doi: 10.1158/0008-5472.CAN-08-2287. Review.

8.

Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.

Wang W, Figg WD.

Cancer Biol Ther. 2008 Jul;7(7):1004-5. Review.

9.

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ.

J Natl Cancer Inst. 2011 Feb 16;103(4):334-46. doi: 10.1093/jnci/djq509. Epub 2010 Dec 23.

PMID:
21183737
10.

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM.

J Clin Oncol. 2011 Aug 1;29(22):3008-15. doi: 10.1200/JCO.2010.34.2980. Epub 2011 Jun 27.

11.

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB.

J Clin Oncol. 2010 Aug 1;28(22):3570-6. doi: 10.1200/JCO.2009.27.2997. Epub 2010 Jul 6.

12.

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.

Ter Brugge P, Kristel P, van der Burg E, Boon U, de Maaker M, Lips E, Mulder L, de Ruiter J, Moutinho C, Gevensleben H, Marangoni E, Majewski I, Józwiak K, Kloosterman W, van Roosmalen M, Duran K, Hogervorst F, Turner N, Esteller M, Cuppen E, Wesseling J, Jonkers J.

J Natl Cancer Inst. 2016 Jul 5;108(11). doi: 10.1093/jnci/djw148. Print 2016 Nov.

PMID:
27381626
13.

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6. doi: 10.1073/pnas.1305170110. Epub 2013 Oct 1.

14.

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J.

Lancet. 2010 Jul 24;376(9737):235-44. doi: 10.1016/S0140-6736(10)60892-6. Epub 2010 Jul 6.

PMID:
20609467
15.

Advances in PARP inhibitors for the treatment of breast cancer.

Dizdar O, Arslan C, Altundag K.

Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20. Review.

PMID:
26485111
16.

PARP inhibitors in the management of breast cancer: current data and future prospects.

Livraghi L, Garber JE.

BMC Med. 2015 Aug 13;13:188. doi: 10.1186/s12916-015-0425-1. Review.

17.

Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.

Clark CC, Weitzel JN, O'Connor TR.

Mol Cancer Ther. 2012 Sep;11(9):1948-58. doi: 10.1158/1535-7163.MCT-11-0597. Epub 2012 Jul 9.

18.

BRCA in breast cancer: from risk assessment to therapeutic prediction.

Diamond JR, Borges VF, Eckhardt SG, Jimeno A.

Drug News Perspect. 2009 Dec;22(10):603-8. doi: 10.1358/dnp.2009.22.10.1440985. Review.

PMID:
20140280
19.

A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.

Nicum S, Roberts C, Boyle L, Kopijasz S, Gourley C, Hall M, Montes A, Poole C, Collins L, Schuh A, Dutton SJ; 6MP Collaborative Group.

BMC Cancer. 2014 Dec 19;14:983. doi: 10.1186/1471-2407-14-983.

20.

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T.

Cancer Res. 2008 Apr 15;68(8):2581-6. doi: 10.1158/0008-5472.CAN-08-0088.

Supplemental Content

Support Center